Wechselberger C, Messner B, Bernhard D
Toxics. 2023; 11(12).
PMID: 38133357
PMC: 10747024.
DOI: 10.3390/toxics11120956.
Bello K, Wilke M, Simoes R, Landim-Vieira M, Langa P, Stefanon I
Front Physiol. 2023; 14:1260509.
PMID: 37929206
PMC: 10622797.
DOI: 10.3389/fphys.2023.1260509.
Niede R, Benbi D
AIMS Public Health. 2023; 9(4):758-789.
PMID: 36636150
PMC: 9807406.
DOI: 10.3934/publichealth.2022052.
Habeeb E, Aldosari S, Saghir S, Cheema M, Momenah T, Husain K
Toxicol Rep. 2022; 9:521-533.
PMID: 35371924
PMC: 8971584.
DOI: 10.1016/j.toxrep.2022.03.019.
Zhou Y, Wu W, Cheng J, Liang L, Cen J, Chen C
Aging (Albany NY). 2020; 12(13):13076-13089.
PMID: 32614786
PMC: 7377899.
DOI: 10.18632/aging.103398.
The Association of Paraoxonase-1 Polymorphism with Carotid Artery Stenosis among Elderly Chinese Population.
Sun J, Wang L, Yang Q, Zhou T, Ding X, Yang K
Oxid Med Cell Longev. 2020; 2020:3084120.
PMID: 32148648
PMC: 7049405.
DOI: 10.1155/2020/3084120.
Relationship between rs854560 Gene Polymorphism and Tobacco Smoking with Coronary Artery Disease.
Iwanicka J, Iwanicki T, Niemiec P, Nowak T, Krauze J, Grzeszczak W
Dis Markers. 2017; 2017:1540949.
PMID: 29118461
PMC: 5651137.
DOI: 10.1155/2017/1540949.
Mercury Exposure and Heart Diseases.
Genchi G, Sinicropi M, Carocci A, Lauria G, Catalano A
Int J Environ Res Public Health. 2017; 14(1).
PMID: 28085104
PMC: 5295325.
DOI: 10.3390/ijerph14010074.
Role of mercury toxicity in hypertension, cardiovascular disease, and stroke.
Houston M
J Clin Hypertens (Greenwich). 2011; 13(8):621-7.
PMID: 21806773
PMC: 8108748.
DOI: 10.1111/j.1751-7176.2011.00489.x.
The association of the PON1 Q192R polymorphism with coronary heart disease: findings from the British Women's Heart and Health cohort study and a meta-analysis.
Lawlor D, Day I, Gaunt T, Hinks L, Briggs P, Kiessling M
BMC Genet. 2004; 5:17.
PMID: 15214960
PMC: 449704.
DOI: 10.1186/1471-2156-5-17.
Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor.
Deakin S, Leviev I, Brulhart-Meynet M, James R
Biochem J. 2003; 372(Pt 2):643-9.
PMID: 12639220
PMC: 1223427.
DOI: 10.1042/BJ20021670.
Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Williams D, Feely J
Clin Pharmacokinet. 2002; 41(5):343-70.
PMID: 12036392
DOI: 10.2165/00003088-200241050-00003.